When did Risperdal’s patent protection end, letting generics enter?
Risperdal (risperidone) has multiple patents listed in different jurisdictions, so “patent expiration” depends on which patent family and which country (for example, US vs. EU). Generic risperidone products were able to launch only after the relevant exclusivities/patents (and any regulatory exclusivity tied to the original New Drug Application) expired or were successfully challenged under the applicable system. Without the specific country and patent/patent-number you mean, there is no single expiration date that applies to every market.
Is there one “patent expiration date” for all generic risperidone versions?
No. Even if the original drug’s core composition of matter is past its longest protection, other patents can delay specific generic launches in certain forms (for example, different strengths, dosing regimens, or specific extended-release formulations). The timing also changes based on how regulators handle patent lists and exclusivity (including periods of marketing protection that are not strictly the same thing as patent expiration).
How do you find the exact risperidone/Risperdal expiration date for your country?
To pin down the correct date, you typically need:
- The country/market you care about (US, UK, EU, etc.).
- The exact product (immediate-release tablets vs. other formulations).
- The specific patent(s) or exclusivity listed for that product in the regulator’s patent register.
- The regulatory approval path the generic used (if it was an “abbreviated” application designed to rely on the original clinical data, it often requires navigating listed patents).
Why would some generics launch later than others even after “Risperdal goes generic”?
Late-launch can happen if:
- A newer patent covers a specific formulation, method of use, or manufacturing process.
- The generic product targets a different dosage form or release profile than the first generic entrant.
- There are patent disputes or settlements that delay the effective “entry” date in that market.
What to do if you’re trying to verify a specific generic’s launch eligibility
If you’re looking at a particular generic risperidone product and want to know why it launched on a certain date, the most reliable approach is to check:
- The regulator’s patent register and exclusivity records for that exact branded reference product and formulation.
- Any publicly available litigation/settlement details associated with the abbreviated approval pathway in that jurisdiction.
Can you ask for a precise expiration date if you share details?
If you tell me the country (e.g., US) and whether you mean Risperdal immediate-release tablets or another formulation, I can help you narrow down which patents/exclusivities typically govern generic entry for that specific product type.